Supplier
Procare Pharmacy Direct, LLC.
Procare Pharmacy Direct, LLC. was paid $227.31M by Medicaid between Jan 2018 and Dec 2024, across 60 billing codes. Its largest line is J0584, Injection, burosumab-twza 1 mg — 32% of everything it billed.
33Billing provider infoPROCARE PHARMACY DIRECT, LLC.
MONROEVILLE, PA 15146
MONROEVILLE, PA 15146
33aNPI1043382302assigned 11/14/2006
33bProvider typeCommunity/Retail Pharmacy
28Total paid$227.31M
24GClaims82,891
24DCodes billed60
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Community/Retail Pharmacy providers in Pennsylvania
Rank by total paid#1 of 44
Median peer was paid$461.37
This provider vs. median492,692×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official AYCOCK, BRANDON controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,063 | $14.10M | |
| 2019 | 14,820 | $22.46M | |
| 2020 | 14,439 | $29.51M | |
| 2021 | 14,738 | $41.30M | |
| 2022 | 11,798 | $45.84M | |
| 2023 | 7,468 | $39.99M | |
| 2024incomplete | 6,565 | $34.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0584 | Injection, burosumab-twza 1 mg | 32% | 3,527 | 2,333 | $72.39M |
| J0638 | Injection, canakinumab, 1 mg | 8.7% | 910 | 793 | $19.84M |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | 8.2% | 6,489 | 5,149 | $18.63M |
| J7170 | Injection, emicizumab-kxwh, 0.5 mg | 7.3% | 763 | 439 | $16.59M |
| J3285 | Injection, treprostinil, 1 mg | 5.1% | 2,757 | 1,496 | $11.52M |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | 4.7% | 11,978 | 11,001 | $10.75M |
| J2357 | Injection, omalizumab, 5 mg | 4.4% | 3,752 | 2,935 | $10.02M |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 3.6% | 9,188 | 8,531 | $8.28M |
| J2323 | Injection, natalizumab, 1 mg | 2.8% | 859 | 812 | $6.46M |
| J2182 | Injection, mepolizumab, 1 mg | 2.4% | 1,744 | 1,538 | $5.50M |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 2.4% | 705 | 645 | $5.34M |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | 2.2% | 1,047 | 952 | $5.06M |
48 more codes
| J0490 | Injection, belimumab, 10 mg | 2.1% | 1,342 | $4.85M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 2.0% | 4,142 | $4.45M |
| J2350 | Injection, ocrelizumab, 1 mg | 1.9% | 137 | $4.30M |
| J0178 | Injection, aflibercept, 1 mg | 1.6% | 1,338 | $3.65M |
| J2315 | Injection, naltrexone, depot form, 1 mg | 1.3% | 2,144 | $2.92M |
| J0775 | Injection, collagenase, clostridium histolyticum, 0.01 mg | 1.2% | 271 | $2.67M |
| 90378 | <1% | 838 | $2.00M | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 585 | $1.20M |
| J0517 | Injection, benralizumab, 1 mg | <1% | 252 | $1.18M |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | <1% | 612 | $1.11M |
| J0180 | Injection, agalsidase beta, 1 mg | <1% | 51 | $1.07M |
| Q9991 | Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg | <1% | 520 | $930K |
| J0897 | Injection, denosumab, 1 mg | <1% | 478 | $802K |
| J3590 | Unclassified biologics | <1% | 111 | $709K |
| J2356 | Injection, tezepelumab-ekko, 1 mg | <1% | 191 | $661K |
| J7296 | Levonorgestrel-releasing intrauterine contraceptive system, (kyleena), 19.5 mg | <1% | 700 | $637K |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 309 | $621K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 103 | $493K |
| J7301 | Levonorgestrel-releasing intrauterine contraceptive system (skyla), 13.5 mg | <1% | 522 | $374K |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 59 | $353K |
| J0578 | Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy | <1% | 185 | $323K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 42 | $238K |
| J3357 | Ustekinumab, for subcutaneous injection, 1 mg | <1% | 13 | $236K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 59 | $220K |
| J3490 | Unclassified drugs | <1% | 52 | $126K |
| J2794 | Injection, risperidone (risperdal consta), 0.5 mg | <1% | 109 | $126K |
| Q0513 | Pharmacy dispensing fee for inhalation drug(s); per 30 days | <1% | 418 | $95K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 30 | $86K |
| J0577 | Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy | <1% | 109 | $65K |
| J0491 | Injection, anifrolumab-fnia, 1 mg | <1% | 12 | $56K |
| S9379 | Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 213 | $48K |
| J7518 | Mycophenolic acid, oral, 180 mg | <1% | 1,330 | $44K |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | <1% | 4,401 | $40K |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | <1% | 532 | $37K |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | <1% | 9,745 | $37K |
| J7517 | Mycophenolate mofetil, oral, 250 mg | <1% | 2,610 | $31K |
| 99601 | <1% | 181 | $27K | |
| J1559 | Injection, immune globulin (hizentra), 100 mg | <1% | 90 | $24K |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | <1% | 1,793 | $14K |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 153 | $14K |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | <1% | 412 | $12K |
| K0455 | Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol) | <1% | 385 | $10K |
| J7515 | Cyclosporine, oral, 25 mg | <1% | 378 | $6K |
| J7520 | Sirolimus, oral, 1 mg | <1% | 52 | $3K |
| S9357 | Home infusion therapy, enzyme replacement intravenous therapy; (e.g., imiglucerase); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 95 | $3K |
| J7699 | Noc drugs, inhalation solution administered through dme | <1% | 28 | $3K |
| S5000 | Prescription drug, generic | <1% | 112 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 928 | $881.68 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAYCOCK, BRANDON (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Procare Pharmacy, L.L.C. | Honolulu, HI | $41.83M |
| Caremark, L.L.C. | Mt Prospect, IL | $34.08M |
| Caremark, L.L.C. | Redlands, CA | $19.87M |
| Caremark, L.L.C. | Tampa, FL | $7.28M |
| Caremark, L.L.C. | Fairfield, NJ | $3.43M |
| Caremark L.L.C. | Raleigh, NC | $2.69M |
| Caremark L.L.C. | Lenexa, KS | $2.54M |
| Caremark, L.L.C. | Milford, MA | $2.20M |
| Caremark, L.L.C. | Bartlett, TN | $1.96M |
| Procare Pharmacy, LLC. | Birmingham, AL | $623K |
| Procare Pharmacy, L.L.C. | Portland, ME | $109K |
| Procare Pharmacy LLC | Boston, MA | $724.47 |
| Caremark, LLC | Mt. Prospec, IL | $76.40 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.